5M PRODUCT
Ribziff D Tablet
Antiulcerants PHARMACEUTICAL PRODUCT

Ribziff D Tablet

Strength 20MG / 10MG, 20MG / 30MG
Published by 5M Biotech India
Last updated 27 October 2026
Company Profile →
PRODUCT INFORMATION

About Ribziff D Tablet

Product information published by 5M Biotech India.

Active Ingridient Rabeprazole sodium and Domperidone
Brand
Country of origin India
Form Oral Tablet

Ribziff D Tablet is a prescription medication used to treat gastroesophageal reflux disease (GERD), acid reflux, and peptic ulcers. It contains a combination of Rabeprazole sodium and Domperidone.

Clinical Uses

Ribziff D Tablet is used to treat acid-related digestive disorders such as gastroesophageal reflux disease (GERD), acid reflux, and peptic ulcers. It is also used to treat dyspepsia (indigestion) and nausea and vomiting. It helps relieve digestive problems such as heartburn, sour stomach, and upper abdominal discomfort.

Dose Options

Ribziff D Tablet is available in the following strengths:

  • 20mg / 10mg: Rabeprazole sodium 20 mg and Domperidone 10 mg
  • 20mg / 30mg: Rabeprazole sodium 20 mg and Domperidone 30 mg

How It Works

Ribziff D Tablet is a combination of Rabeprazole sodium and Domperidone. Rabeprazole belongs to a drug class called proton pump inhibitors (PPIs) that act on acid-producing cells in your stomach lining. It works by blocking the tiny acid pumps that release acid in the stomach. This helps reduce acidity and acid-related problems.

Domperidone is a dopamine receptor antagonist that reduces nausea and vomiting by improving the movement of the stomach and intestines.

Side Effects

A few side effects of Ribziff D Tablet include:

  • Diarrhea
  • Stomach pain
  • Dry mouth
  • Dizziness
  • Headache
  • Gas and constipation
  • Muscle or joint pain

Consult your doctor if any of your side effects do not improve or become persistent.

Precautions & Warnings

  • Avoid consuming alcohol while taking Ribziff D Tablet as it may cause dehydration and increase stomach acid.
  • Ribziff D Tablet is not safe during pregnancy. Consult your doctor on whether you can take it or not.
  • Use of Ribziff D Tablet is not safe in breastfeeding mothers, as it may pass into the breast milk, harming the baby.
  • Ribziff D Tablet should be used with caution in severe kidney disease patients.
  • Patients with Liver disease should avoid taking Ribziff D Tablet.
  • Heart patients should use this medicine with caution.
  • Ribziff D Tablet may cause dizziness or affect your vision, so avoid driving or operating machinery.
  • Ribziff D Tablet is not recommended in children.

Drug Interactions

Inform your doctor about any other medicines you are taking. Ribziff D Tablet can interact with the following medicines:

  • Ketoconazole
  • Erythromycin
  • Clarithromycin
  • Clopidogrel
  • Warfarin
  • Atazanavir
  • Ritonavir
  • Digoxin

Disclaimer

At 5M Biotech India we provide accurate, reliable and expert reviewed information. However, all our content on this platform is intended for informational purposes only and is not professional medical advice, diagnosis or treatment. While we make efforts to maintain accuracy, the information may contain mistakes, omissions or may not reflect the latest developments. Always consult your doctor regarding any medical concerns.

All medicine names, trademarks, and registered trademarks displayed on 5M Biotech India are property of their respective owners. 5M Biotech India and its operator are not affiliated with, endorsed by or authorized by any such trademark owners unless stated expressly. Any reference to trademarks or product names is made for informational purposes. No sponsorship, commercial relationship, approval or association with any trademark owner should be inferred. Information provided herein does not constitute advertising, promotion or an offer for sale of any medicinal goods and is intended solely for general informational purposes.

All trademarks, trade names, and brand names displayed on this website are used strictly in accordance with the applicable provisions of the Trade Marks Act, 1999, including Sections 30 and 30(1) relating to permitted and fair use. The respective trademark ownership has been duly and accurately identified under the “Manufacturer/TM Owner” section in compliance with applicable statutory requirements.

Publisher 5M Biotech India
Last Updated 27 October 2026
Product Record #724
Therapeutic Area Antiulcerants
PRODUCT ENQUIRY

Discuss Ribziff D Tablet